Form D · Other
NeuroView Technology, Inc.
Englewood, NJ · CIK 0001744796
Offering snapshot reported Dec 20, 2023 · SEC filing
- Reported sold
- $250K Offering amount: $4.82M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 13, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 20, 2023 | Initial | $250,002 | No comparison | 1 | SEC filing |
| Jun 29, 2018 | Initial | $304,489 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-500270
Source: Form D, filed Dec 20, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Werner Doyle, M.D. | Director |
| Mark Goldstone | Director |
| James Karwel | Director, Executive |
| Ruben Kuzniecky, M.D. | Director, Executive |
| Steve Pacia, M.D. | Director |
| Louis Rauchenberger | Director |
Issuer details
Industry: Other (See others in industry)
Address:
101 Hillside Avenue
Englewood, NJ, 07631
Englewood, NJ, 07631